

University of Groningen

Targeting brain death-induced injury

van Erp, Anne Cornelia

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2018

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

van Erp, A. C. (2018). *Targeting brain death-induced injury*. [Thesis fully internal (DIV), University of Groningen]. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

CHAPTER

7

The crosstalk between ROS and autophagy in the field of transplantation medicine

Anne C. Van Erp
Dane Hoeksma
Rolando A. Rebolledo
Petra J. Ottens
Ina Jochmans
Diethard Monbaliu
Jacques Pirenne
Henri G.D. Leuvenink
Jean-Paul Decuypere

Published in Oxidative Medicine and Cellular Longevity
on 19 December 2017
DOI: 10.1155/2017/7120962

ABBREVIATIONS

ALT	Alanine Aminotransferase
AMPK	AMP-Activated Kinase
DBD	Donation after Brain Death
DCD	Donation after Cardiac Death
DGF	Delayed Graft Function
ECD	Extended Criteria Donation
GLDH	Glutamate Dehydrogenase
HMP	Hypothermic Machine Perfusion
HRS	Hydrogen-Rich Saline
HTK	Histidine-Tryptophan-Ketoglutarate
IPoC	Ischemic Postconditioning
IRI	Ischemia-Reperfusion Injury
LC3-PE	Phosphatidylethanolamine-Conjugated LC3
LC3-II	See LC3-PE
ROS	Reactive Oxygen Species
T3	3,3',5-Triiodo-L-thyronine
MMF	Mycophenolate Mofetil
MP	Methylprednisolone
MPG	N-2-Mercaptopropionyl Glycine
mTOR	Mammalian Target of Rapamycin
NO	Nitric Oxide
Ub	Ubiquitination
UW	University of Wisconsin

ABSTRACT

Many factors during the transplantation process influence post-transplant graft function and survival, including donor type and age, graft preservation methods (cold storage - machine perfusion) and ischemia-reperfusion injury. Successively, they will lead to cellular and molecular alterations that determine cell and ultimately organ fate. Oxidative stress and autophagy are implicated in post-transplant outcome since they are both affected by the stress responses triggered in each step (donor, preservation, recipient) of the transplantation process. Furthermore, oxidative stress influences autophagy and vice versa. Interestingly, both processes have positive as well as negative effects on graft outcome, suggesting they are tightly linked during the transplantation process. In this review, we discuss the importance, regulation and crosstalk of oxidative signals and autophagy in the field of transplantation medicine.

INTRODUCTION

For patients with end-stage organ disease, organ transplantation has become the treatment of choice. However, the success of transplantation is limited by a global shortage of suitable organs as well as loss of grafts following transplantation due to primary non-function or rejection. The gap between supply and demand has steadily increased over the years and as a result, so has the number of patients on the waiting list^{1,2}. This is an alarming increase, as organ transplantation significantly improves a patient's quality of life as well as survival rate when compared to patients who remain on the waiting list³⁻⁵. These problems can be addressed by increasing the use of older and higher risk donors, while simultaneously improving graft longevity.

Oxidative stress levels correlate with graft survival in all steps of the transplantation process including in the donor⁶⁻¹⁶, during preservation^{17,18}, and reperfusion in the recipient. In donation after brain death (DBD) donors, brain death pathophysiology leads to increased renal oxidative damage markers which correlate with acute rejection, delayed graft function (DGF) and allograft function⁶⁻¹⁶. In donation after cardiac death (DCD) donors, cardiac arrest causes warm ischemia which is associated with impaired graft function and higher mortality rates⁶⁻⁸. Increased oxidative stress markers are evident in organs from DCD donors, but no evidence is available correlating them with outcome. Clinically proven donor treatments that benefit graft survival include dopamine administration and hypothermic cooling of DBD donors, of which the effects could be related to modulation of oxidative stress^{19,20}.

Organ grafts suffer additional ischemic injury during preservation. Prolonged duration of cold ischemia is considered an independent risk factor for a non-functioning or dysfunctional transplant, particularly in marginal or extended criteria donation (ECD) donors²¹. These side effects have recently led to the implementation of hypothermic machine perfusion (HMP). HMP has clear benefits over static cold storage, as evidenced by improved graft function and survival rates in kidney transplantation^{22,23}, as well as reduced oxidative stress markers in experimental^{24,25} and clinical²⁶ liver preservation.

In the recipient, the mechanism of reperfusion injury, labeled ischemia-reperfusion (IR) injury (IRI), has been reported in most solid transplantable organs²⁷⁻³¹ and is mediated by reactive oxidative species (ROS) production most likely from donor-derived vascular cells^{32,33}, followed by a second burst of ROS probably produced by the recipient's phagocytes^{29,34-41}. However, mitochondria are also implicated in ROS^{29,42-45} as well as nitric oxide (NO) production during IRI⁴⁶⁻⁴⁸. Despite overwhelming experimental evidence on the beneficial effects of attenuating ROS during this phase, clinical evidence remains limited.

Oxidative stress is a known inducer of autophagy. Even though autophagy regulation during the transplantation process is only starting to be understood, several autophagy modulators have already been implemented. In this review, we will first introduce autophagy in the context of the transplantation process and cover the current knowledge during each of these stages. Secondly, we will touch upon the complex, intertwined and reciprocal relationship of oxidative stress and autophagy in the field of transplantation medicine while covering the therapeutic strategies that target each of these pathways.

AUTOPHAGY AND TRANSPLANTATION

Autophagy: importance and mechanisms

Several pathways of autophagy exist⁴⁹, of which macro-autophagy is the best studied (and which will simply be referred to as ‘autophagy’ for the remainder of this manuscript). It involves the formation of double-membranous vesicular ‘autophagosomes’ that occlude and transport the soon-to-be degraded material to the lysosomes (Fig 1). This process is normally constitutively active in cells, albeit at a low basal level, thereby maintaining cellular homeostasis (Fig 1). However, autophagy is stimulated upon stress through several signaling pathways, of which the mammalian target of rapamycin (mTOR) pathway is the most notable in response to nutrient stress. Energy deprivation attenuates mTOR signaling through the activation of AMP-activated kinase (AMPK), which also directly stimulates autophagy by the phosphorylation of the autophagy-initiating ULK1 complex.

Another initiation complex is constituted by Vps34 (Class III PI3K) and Beclin 1, an autophagy-specific BH3-only domain-containing protein that is inhibited by several anti-apoptotic Bcl-2 family proteins (Fig 1). As such, apoptotic signals can also trigger autophagy, in which the autophagic response often precedes apoptosis as a first attempt to survival⁵⁰. However, when autophagy fails, cells will eventually activate apoptosis, which may even occur with the help of the still active autophagic machinery. This shows that autophagy may switch from a pro-survival to a pro-death pathway under certain conditions⁵¹, although the exact mechanism, context, and details on this autophagy-dependent cell death remains currently elusive.

Following initiation, the formation of autophagosomes is mediated by the Atg5-Atg12 complex and the formation of phosphatidylethanolamine-conjugated LC3 (‘LC3-PE’ or ‘LC3-II’) (Fig 1). The latter is generally used as a marker for autophagy, as it is distinguishable from its precursor LC3-I on Western blot and its fluorescent labeling allows visualization of autophagosomes as GFP-LC3 punctae. Despite delipidation of LC3-II on the outer membrane by Atg4, LC3-II remains attached to the inner autophagosomal membranes even after fusion of autophagosomes with lysosomes. Therefore, an increase of LC3-II or GFP-LC3 punctae




Figure 1. Overview of the autophagy process. Autophagy is initiated by the ULK1 complex, which is negatively regulated by mTOR, but positively by AMPK. This way it responds to nutrient or energy deprivation. In addition, the Class III PI3K complex requires Beclin 1, which is inhibited by Bcl-2. During elongation Atg5-Atg12 and LC3-II are required. The latter is attached to the autophagosomal membranes. LC3-II will be delipidated on the outer membrane by Atg4 (a process inhibited by H₂O₂) but remains on the inner membrane and will be degraded inside the lysosomes. Mitochondria can be also degraded (mitophagy), via recruitment of Sqstm1/p62. The latter protein also recruits Keap1 for degradation, thereby enabling Nrf-2-dependent anti-oxidant transcription. Eventually autophagosomes fuse with lysosomes, the cellular structures in which degradation takes place. The levels of autophagy determine the outcome on cellular injury and needs to stay balanced in order not to provoke death.

7

can signify stimulation of autophagy or attenuation of the final steps in autophagy (e.g. inhibition of fusion), leading to an accumulation of autophagosomes without any true upregulation of autophagy. Therefore, prudence is advised when interpreting autophagy data because the dynamic character of the ‘autophagic flux’ should be taken into consideration⁵².

As the graft endures several types of stress during transplantation, it is evident that the protective properties of autophagy might be important in restoring cellular homeostasis and function in the organ grafts. Interestingly, DGF increases with donor (and recipient) age as ageing leads to increased susceptibility towards cellular stress^{53,54}. An underlying mechanism for this increased vulnerability of aged organs is the age-related reduction in autophagy⁵³. It has therefore been suggested that pharmacological stimulation of autophagy could reduce graft injury and promote function⁵⁵. However, as excessive autophagy may detrimentally impact cellular fate through autophagy-dependent cell death (Fig 1), it is important to first understand the dynamics and role of autophagy to determine whether autophagy stimulation or inhibition is the best option in transplantation.

Autophagy in the donor

The autophagic response in the donor is likely the result of donor-related characteristics including donor age, gender, comorbidities and donor type of death. Of course, ischemic time is strongly prolonged in DCD compared to DBD grafts, which could partially explain the stronger injury in DCD grafts. This is important, since autophagy's dynamics and role (protective vs. detrimental) during ischemic stress are likely dependent on the extent of ischemic injury, at least in kidney^{56,57} and heart⁵⁸. As DCD donors suffer more extensive anoxic injury compared to DBD donors, this could trigger autophagy-dependent cell death (Fig 2) and suggests that therapeutic strategies involving autophagy modulation are strongly donor type-dependent.

Additionally, the higher post-transplant injury in ECD (e.g. older) kidneys may be attributed to a decline in autophagy activity with age⁵⁹⁻⁶², justifying autophagy stimulation as the preferred strategy in these donors. Compared to young mice, old mice showed a decreased autophagic response in terms of vacuole formation and elimination after stimulation of these processes with vinblastine

and Triton X-100⁶¹. In line with this, hypoxia-induced injury was reduced by starvation-induced autophagy in older kidneys⁶³. Besides donor age, a less studied, but seemingly equally important feature is the gender of the donor. In a cardiac IRI study in mice, male and females showed different autophagic activity: male mice show a decrease and female mice an increase in LC3-II levels⁶². We have also observed gender differences in the kidney, with a decrease in male, but unchanged LC3-II levels in female Sprague-Dawley rats subjected to 45 min of ischemia followed by 3 h of reperfusion (Fig 3). As such, therapeutic strategies involving autophagy modulation may differ in organs coming from male and female donors (Fig 2).

Autophagy during organ preservation

Mixed reports exist on the effects of cold ischemia on autophagy. In mouse kidneys, cold ischemia resulted in increased autophagy markers⁶⁴. Interestingly, repression of autophagic flux by means of lysosomal inhibitor bafilomycin A1 resulted in less apoptosis, suggesting that autophagy could trigger cell death during renal cold ischemia. Similar findings were observed in cold preserved rat lungs⁶², where prolonged preservation resulted in increased autophagy associated with cell death. Alternatively, decreased markers of autophagy were




Figure 2. Regulation of oxidative signals and autophagy by transplantation-related factors. Excessive autophagy and/or oxidative stress can lead to increased graft injury and tilt the balance to the right. To tilt the balance towards survival, excessive signals need to be reduced towards protective levels of oxidative signals and autophagy.




Figure 3. Gender differences in autophagy activation in response to ischemia-reperfusion injury. Western blot expression of autophagy-related proteins LC3-I, LC3-II, and Sqstm1/p62 in female (left) and male (right) Sprague-Dawley rat kidneys subjected to 45 min of warm ischemia (WI) followed by 3h of reperfusion (3h R). Each lane represents an independent experiment ($N = 6$). Quantification of p62 (left) or LC3-II (right) over GAPDH levels, compared to the mean of the corresponding Sham group. LC3-II and p62 are clearly lower in the WI group of females compared to the male WI group. Results are presented as mean \pm SD ($N = 6$ per group) (* $p < 0.05$; *** $p < 0.001$).

found following cold ischemia in marginal, steatotic rat livers⁶⁵⁻⁶⁷. Induction of autophagy in these marginal livers by means of melatonin and trimetazidine addition to the cold preservation medium improved organ quality as evidenced by lower levels of injury markers alanine aminotransferase (ALT) and glutamate dehydrogenase (GLDH)⁶⁷. These benefits were attenuated when autophagy was suppressed with bafilomycin A1⁶⁷. Furthermore, oxygen insufflation of the cold preservation medium of marginal livers reversed the suppression of autophagy and functional impairment⁶⁶, suggesting beneficial effects of autophagy induction. These studies suggest that the differential effects of autophagy activation might be organ-dependent (Fig 2; see also *autophagy in the recipient*) and closely associated with organ function and cell death.

Autophagy in the recipient

The role of autophagy in IRI is best studied in the context of the transplantation process. However, its dynamics and roles remain elusive and are likely dependent on different factors. Firstly, when studying the nature of autophagy dynamics, i.e. whether autophagy is stimulated or attenuated during IRI, research suggests that autophagy is mostly upregulated in the heart⁶⁸ and the kidney⁵⁶, while findings in the liver are conflicting⁶⁵. These discrepancies might be explained by several reasons (described in more detail in⁵⁶), including the difficulty of measuring the dynamic process of autophagic flux in static samples. Indeed, an increase in LC3-II could equally well indicate stimulated autophagy as well as inhibited autophagic flux. *In vivo* experiments with chloroquine (an inhibitor of autophagosome-lysosome fusion, mimicking inhibited autophagic flux) suggests that autophagy inhibition might occur in the heart⁶⁹ and liver⁷⁰. Moreover, as autophagy often fluctuates during prolonged stress, multiple time points post-reperfusion should be investigated⁵⁶.

Secondly, conflicts arise when looking at the proposed role of autophagy during IRI. In hepatic IRI models, most studies indicate a protective role for autophagy⁶⁵, whereas both protective and detrimental roles (or both, see further) are assigned to autophagy in the heart and kidney^{56,68}. Besides the difficulties in measuring autophagic flux, non-specific chemical modulators of autophagy also have secondary effects on mTOR (e.g. rapamycin), PI3K (e.g. 3-methyladenine) or lysosomal and endocytic function (bafilomycin A1 and chloroquine)⁵⁶. Even data in conditional autophagy knockout mice (e.g. atg5^{-/-}) are important to interpret with caution. As autophagy is an important mechanism for basal cellular homeostasis in cells (Fig 1), any stress addition in these models will likely lead to more injury than in wild type. In this context, proximal tubule-specific Atg5 KO mice displayed strange concentric membranous structures in targeted cells⁷¹, suggesting unhealthy cells.

Thirdly, several reports propose a dual role for autophagy in IRI, dependent of the extent of the stress^{56,72}; i.e. mild IR stress leads to protective autophagy stimulation, while severe

stress could trigger a switch towards autophagy-dependent cell death (Fig 1,2). In this respect, the duration of ischemia prior to transplantation is an important factor to consider. The longer the ischemic period, the more severe the reperfusion injury, which seems associated mostly with a detrimental role for autophagy, at least in kidneys⁵⁶. Besides the extent of the stress, the type of stress that initiates autophagy is also important. This is evident in the heart, where autophagy-dependent cell death during reperfusion seems to be dependent on levels of Beclin 1, which initiation is likely determined by apoptotic factors. Protective autophagy on the other hand seems to be dependent on AMPK activation and would therefore be related to changes in energy status (Fig 2)⁷².

Finally, autophagy during IRI is strongly determined by the degree of autophagy-dependency of the organs and even of different cell types within an organ (Fig 2). In renal podocytes for example, autophagy is much more important for cellular homeostasis (as these cells are post-mitotic) than in tubular cells. Also, cardiomyocytes are strongly dependent on basal autophagy, while hepatocytes rely more on stress-induced autophagy. In this respect, liver cells might have different mechanisms controlling autophagy as they can tolerate more severe stress than other organs. This might explain the more consistent data regarding the protective role for autophagy in this organ compared to the kidney and the heart during IR.

AUTOPHAGY AND OXIDATIVE STRESS IN TRANSPLANTATION

The relationship between autophagy and oxidative stress

Both oxidative stress and autophagy have been described as both protective and detrimental pathways in response to cellular stressors^{34,73}. Therefore, it is feasible that the fine balance of oxidative stress levels and autophagy activation plays an important role in the long-term function and survival of organ grafts. This makes modulation of these pathways interesting targets to predict or improve graft function and survival after transplantation. Surprisingly, the only currently known direct redox-based regulation of autophagy is the inhibitory oxidation of Atg4 by H₂O₂, which suppresses the delipidation of LC3-II⁷⁴ (Fig 1). Furthermore, H₂O₂ is also proposed to stimulate autophagy initiation directly via regulation of AMPK⁷⁵ (Fig 1).

In a slower, more indirect fashion, oxidative stress also regulates transcription of Beclin 1 and LC3⁵⁵. Together, these protective, pro-autophagic effects are achieved with subtle changes in ROS. Conversely, acute and persistent ROS production can oxidatively modify macromolecules in such a way that they are only partially degraded by the autophagic/lysosomal pathway. This produces an indestructible product known as lipofuscin, which accumulates within the lysosomes, hampers their function and sustains or even exacerbates oxidative injury⁷⁶. Together, this suggests that the amount of ROS produced will determine

whether autophagy will be activated or inhibited and whether it prevents or amplifies further damage. Besides the regulation of autophagy by oxidative molecules, autophagy reciprocally regulates oxidative signals. As it is a clearance mechanism, autophagy may remove oxidatively damaged macromolecules or even entire organelles. Upon excessive ROS production, mitochondria risk severe damage and need to be partially removed⁷⁷. This occurs through the selective autophagic degradation of damaged mitochondrial fragments called 'mitophagy' (Fig 1). This process involves the recruitment of PINK1 and Parkin to the outer mitochondrial membrane where they promote ubiquitination (Ub) of several mitochondrial proteins^{78,79}. This Ub-signal serves as a recognition for Sqstm1/p62, which is an adapter protein for LC3-II (Fig 1). The link between ROS and mitophagy was confirmed in a study on heart failure in mice, describing that p53-induced impairment of mitophagy resulted in mitochondrial dysfunction and increased ROS production^{78,79}.

In addition to mitophagy, autophagy is shown to regulate anti-oxidant responses through interactions of Sqstm1/p62 with Keap1. Sqstm1/p62 recruits Keap1 via interactions with ubiquitinated aggregates, after which Keap1 is degraded via autophagy. Degradation of Keap1 in turn prevents it from ubiquitinating and degrading Nrf2-dependent transcription factors, thereby enabling the anti-oxidant response⁸⁰ (Fig. 1).

Autophagy and oxidative stress in the donor

The accumulation of acute and chronic injuries in the donor leads to increased senescence and reduced organ quality. In ECD donors, this may be due to an increase in age-related oxidative damage¹⁶ (Fig 2) as well as a reduction of autophagic activity and hence the inability to remove oxidatively damaged organelles. This link was shown in kidneys of aged rats, where a high caloric diet exacerbated oxidative damage and aging, whilst autophagy was reduced⁸¹. The opposite was observed in the low caloric group⁸¹. The link between caloric intake and autophagy regulation is interesting, as it highlights how energy deprivation (i.e. glucose and amino acid stress) can initiate protection via autophagy-mediated pathways to restore cellular energy supplies (Fig 2)⁷⁵. In response to starvation, increased activity of the mitochondrial apparatus in turn increases mitochondrial ROS production, which activates autophagy⁷⁵. Interestingly, a proteomics study in brain-dead rodents indicated that both metabolic changes and mitochondrial dysfunction are the two major canonical pathways affected in the kidney of brain-dead donors⁸². Even though no direct line of evidence connects these alterations to autophagy, it is nonetheless feasible that autophagy is indeed modulated in DBD donors.

A recent study from our group showed that treatment of brain-dead rats with thyroid hormone T3, both a metabolic regulator and powerful inducer of autophagy, improved liver




Figure 4. Post-transcriptional reduction of apoptosis and induction of autophagy in the liver of brain-dead rats following T3 treatment, yet no effects in the kidney. Western blot expression of pro-apoptotic protein Bax and autophagy-related proteins LC3-II and SQSTM1/p62 in the liver (A, C) and kidney (B, D), and E) renal injury markers in plasma of T3- or vehicle-pretreated brain-dead rats. Each lane represents an independent experiment. Results are presented as mean \pm SD ($N = 7$ per group) (** $p < 0.01$).

function, while reducing apoptosis and oxidative stress⁸³. In prosecution of this work⁸³, the protective effects of T3 preconditioning in brain-dead rats were indeed accompanied by an induction of autophagy in the liver, as evidenced by increased formation of LC3-II together with decreased (albeit non-significantly) levels of the autophagic substrate SQSTM1/p62 (Fig 4). Interestingly, in the kidney, T3 neither altered autophagy, nor attenuated injury or apoptosis (Fig 4). Therefore, this suggests that T3-induced autophagy is not evident in

the kidney and consequently, neither a reduction in apoptosis nor injury. In contrast, the reduction in apoptosis and injury markers in the liver does appear to be associated with increased hepatic autophagy, suggesting an important role for autophagy stimulation in livers from brain-dead animals. We hypothesize that T3 boosts a transient peak in mitochondrial activity and ROS production, resulting in autophagy induction and subsequent protective effects during brain death in the liver (Fig 5).




Figure 5. Proposed mechanism of T3 preconditioning during brain death in the liver.

This is supported by a recent study by Sinha et al. that showed that T3 induces autophagy via ROS-related pathways in the liver both *in vivo* and *ex vivo*^{84,85}. This phenomenon might not be evident in the brain-dead kidney due to extensive levels of oxidative stress 11, which might push the balance from a protective to a detrimental role for autophagy. This work therefore suggests that triggering oxidative pathways while simultaneously increasing autophagy could be an interesting strategy to improve liver function in DBD donors. In this respect, modulation of (mitochondrial) metabolism by compounds such as T3 might be the key to stimulation of transient ROS and subsequently protective autophagy activation (Fig 2).

Autophagy and oxidative stress during preservation

Since most organs worldwide are still preserved on ice, several developments have been made to reduce ischemic injury during cold storage. The gold standard for preservation solutions in kidney, liver, pancreas and small bowel preservation is University of Wisconsin (UW) storage solution^{22,86}. When comparing UW to Histidine-tryptophan-ketoglutarate (HTK) solution, the use of UW leads to decreased renal apoptosis and was linked to lower graft injury in human renal allografts⁸⁷. UW contains, besides energy supplies (adenosine) and osmotic compounds, the anti-oxidants glutathione and allopurinol^{86,88} (Fig 2). However, the beneficial effects of these compounds are questionable considering their short life-spans and the fact that supplementation of glutathione to UW solution was unable to improve renal transplantation outcomes⁸⁶. Nonetheless, a rodent study on kidney transplantation showed that treatment with hydrogen-rich saline (HRS), a novel anti-oxidant, immediately before ischemia attenuated transplantation-related renal injury and oxidative stress, while simultaneously inducing autophagic markers Beclin 1 and LC3-II⁸⁹. Inhibition of autophagy with chloroquine, attenuated these protective effects of HRS, suggesting that these effects were indeed autophagy-mediated and linked to oxidative stress⁸⁹. Therefore, addition of anti-oxidants

to the preservation solution remains an interesting option to reduce graft injury (Fig 2). Conversely, prolonged cold ischemia of healthy kidneys in UW solution showed increased apoptotic and autophagic cells. In this case, addition of bafilomycin A1 inhibited both autophagy and apoptosis⁶⁴. These studies suggest that for the kidney the extent of cold ischemia injury could dictate whether either autophagy induction (in the case of shorter cold ischemia times) or inhibition (in the case of prolonged cold ischemia times) might be beneficial (Fig 2).

In the liver, cold storage of hepatic cells inhibited autophagic flux in both UW and Celsior solution. However, only Celsior-stored cells re-activated autophagy upon reperfusion, while UW-stored cells displayed impaired lyso-autophagosomal fusion and elevated cell death⁹⁰. Interestingly, pretreatment with simvastatin before cold ischemia led to the restoration of autophagy even in UW solution. This was accompanied by preserved cellular viability⁹⁰, suggesting possible benefits for hepatocytes when autophagy is induced during cold storage. These benefits might be linked to oxidative stress, as simvastatin-induced autophagy in cold-stored rat steatotic livers was accompanied by attenuation of oxidative stress⁹¹, showing a link between ROS reduction and autophagy induction during cold liver preservation. In support of this, a study on liver transplantation in which the preservation medium (IGL-1) was enriched with trimetazidine, a fatty acid oxidation inhibitor, showed reduced oxidative stress yet activation of autophagy accompanied with reduced mitochondrial damage and hepatic injury⁹². These data therefore suggest that during cold storage of the liver, a strategy

is preferred that simultaneously attenuates oxidative stress and stimulates autophagy.

The advantage of HMP over static cold storage has led to an increased implementation of this technique in the clinical setting. However, the lack of oxygen during HMP initiates high metabolic flux and subsequent high ROS production, particularly during the first minutes of reperfusion⁹³. Therefore, benefits of oxygen addition to HMP solution are currently being investigated. Animal studies on liver and kidney HMP indicated that oxygenated HMP reduced mitochondrial flux and subsequent ROS production⁹³⁻⁹⁵. ROS production is also further reduced when grafts are perfused at higher temperatures, such as subnormothermic (25°C) or normothermic (37°C) temperatures^{96,97}. Unfortunately, effects of HMP on autophagy remain unexplored (Fig 2).

Autophagy and oxidative stress in the recipient

As the extent of the oxidative response is dependent on ischemic duration, it is possible that the role of autophagy during IRI is dependent on the extent of oxidative stress. In this case, mild IR stress would trigger protective autophagy to counteract the oxidative damage experienced, for example through autophagy-specific degradation of mitochondria (mitophagy). Regulation of mitophagy is thought to occur via oxidation of cardiolipin^{35,98-100}, which plays a central role by mediating increased mitochondrial ROS release which serves as the signal for mitophagy initiation¹⁰¹. However, upon a very strong oxidative response (during severe reperfusion injury), an energy-dependent process as autophagy is not advised. In this case, autophagy stimulation could deprive much-needed energy, induce still elusive autophagy-dependent cell death mechanisms¹⁰² or lead to the production of toxic lipofusins (Fig2)⁷⁶.

In the liver, IRI induced oxidative stress, autophagy, and apoptosis. These effects were attenuated by pre-treatment with the anti-oxidant astaxanthin, potentially via modulation of the MAPK protein family¹⁰³. In a study on renal IRI, increased oxidant production and autophagy markers were evident which suggests a tight and direct relationship between these two processes in which autophagy serves a protective role against renal oxidative damage¹⁰⁴. In the heart, autophagic flux was analyzed during IRI in the presence of either H₂O₂ or the anti-oxidant N-2-mercaptopropionyl glycine (MPG). H₂O₂ increased, while MPG decreased autophagic flux, suggesting that autophagy is regulated by oxidative signals during cardiac IR. Interestingly, autophagy attenuation (by using heterozygous beclin 1+/- mice) improved injury in this experimental setting¹⁰⁵. Altogether, these findings imply that oxidative signals influence autophagy during IR and might be responsible for the exact role (protective or detrimental) autophagy plays in IRI, depending on the type of organ.

Several modulators of oxidative stress and autophagy have been clinically tested or are

commonly used following transplantation. One method to combat the oxidative burst in recipients is ischemic post conditioning (IPoC), a technique that involves the temporal cessation of blood flow to a remote tissue such as a limb, or locally via constriction of a nearby afferent artery. Despite promising preclinical results of local¹⁰⁶ and remote IPoC¹⁰⁷, clinical trials investigating both techniques did not report improved renal function after transplantation^{106,108}. Interestingly, IPoC also stimulates autophagy in the heart^{109,110}, but this seems to depend on the post-reperfusion time¹¹¹. A clinical study on the addition of the antioxidant human recombinant SOD showed decreased rejection rates and improved survival following cadaveric kidney transplantation, despite mixed preclinical results^{17,112}. These results might be autophagy-dependent, as SOD overexpression resulted in attenuation of starvation-induced autophagy and apoptosis¹¹³.

Many of the compounds given to transplant recipients as part of their immunosuppressive regimen also modulate autophagy. These include calcineurin inhibitors cyclosporine and tacrolimus, mTOR inhibitors sirolimus (rapamycin) and everolimus, mycophenolate mofetil (MMF), and corticosteroids^{73,114}. Cyclosporine is a known autophagy inducer that has now largely been replaced by tacrolimus as the treatment of choice in most European and American transplantation centers, mostly because of its proposed nephrotoxic side effects¹¹⁴. Interestingly, these side effects are thought to be related to increased autophagic clearance and autophagosomes formation, phenomena possibly mediated via oxidative stress and apoptosis^{94,115}. Tacrolimus, on the other hand, was recently identified as an autophagy modulator that acts via activation of transcription factor EB, which in turn increases the expression of both autophagy and lysosomal genes^{116,117}. However, it is likely that this is associated with a mild, beneficial induction of oxidative stress¹¹⁸. The use of rapamycin as well as second generation mTOR inhibitors such as everolimus and deferolimus have been used as part of immunosuppressive therapy mostly for their ability to limit T-cell proliferation, but these compounds also influence autophagy by means of mTOR inhibition. However, the use of rapamycin in animal models of renal IRI and transplantation has yielded questionable results. Some studies suggest that rapamycin improves mitochondrial homeostasis and subsequently, reduces ROS production and cellular senescence⁴⁷. On the contrary, a study on renal transplant recipients suffering from DGF shows that patients who received rapamycin had significantly lower chance to resolve DGF¹¹⁹. Interestingly, combined treatment with tacrolimus or mycophenolate mofetil (MMP), an immunosuppressive drug that is known to activate chaperone-mediated autophagy, enhanced the positive effects of rapamycin^{73,120}. The mixed effect of rapamycin treatment might be attributed to the amount of injury and subsequent extent of autophagy activation⁷³. Finally, corticosteroids have been part of most post-operative and maintenance immunosuppressive regimens over the past years¹²¹. Interestingly, methylprednisolone (MP) both suppresses and stimulates autophagy in animal models⁷³. This difference could be related to the extent of the preceding injury,

or could be dose- and time-dependent, as MP treatment has opposite effects on oxidative injury when it is administered acutely (beneficial) or chronically (damaging) in rat lungs¹²². If and how MP affects autophagy modulation post-transplantation and whether this is influenced by oxidative signals remains to be elucidated.

CONCLUSION

Oxidative stress is an important component of the transplantation process as well as a known inducer of autophagy. Although the exact mechanism behind the complex reciprocal relationship between oxidative stress and autophagy is only beginning to be understood, it seems to play a major role in the different roles autophagy and oxidative signals seem to play during transplantation. The potential protective properties of autophagy and low levels of oxidative stress, yet detrimental effects when excessive activation occurs (Fig 2) make these two processes interesting therapeutic or diagnostic targets in each step of the transplantation process, while their tight interaction supports the possibility to target both pathways with only one compound. However, how these processes are preferentially modulated depends on the specific step in the transplantation process, the type of organ, the age and gender of the donor, the ischemic time and other contributing factors. Therefore, future research should try and decipher the complex, intertwined relationship of oxidative stress and autophagy during the transplantation process. Finding the optimal balance between autophagic and oxidative processes is crucial for optimization of cellular longevity and thereby graft survival.

REFERENCES

1. Eurotransplant. Available at: http://statistics.eurotransplant.org/index.php?search_type=transplants&search_period=by+-year+chart. (Accessed: 6 July 2017)
2. National Data: Donors Recovered in the U.S. by Donor Type. Available at: <https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/#>. (Accessed: 1st March 2017)
3. Wolfe, R. A. et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. *N. Engl. J. Med.* **341**, 1725–1730 (1999).
4. Singer, L. G. Cost-effectiveness and quality of life: benefits of lung transplantation. *Respir Care Clin N Am* **10**, 449–57–v (2004).
5. Yang, L. S., Shan, L. L., Saxena, A. & Morris, D. L. Liver transplantation: a systematic review of long-term quality of life. *Liver Int.* **34**, 1298–1313 (2014).
6. Tennankore, K. K., Kim, S. J., Alwayn, I. P. J. & Kiberd, B. A. Prolonged warm ischemia time is associated with graft failure and mortality after kidney transplantation. *Kidney International* **89**, 648–658 (2016).
7. Marasco, S. F., Kras, A., Schulberg, E., Vale, M. & Lee, G. A. Impact of warm ischemia time on survival after heart transplantation. *Transplantation Proceedings* **44**, 1385–1389 (2012).
8. Morariu, A. M. et al. Early events in kidney donation: progression of endothelial activation, oxidative stress and tubular injury after brain death. *Am J Transplant* **8**, 933–941 (2008).
9. Schuur, T. A. et al. Time-dependent changes in donor brain death related processes. *Am J Transplant* **6**, 2903–2911 (2006).
10. Rebolledo, R. A. et al. Slow induction of brain death leads to decreased renal function and increased hepatic apoptosis in rats. *J Transl Med* **14**, 141 (2016).
11. Hoeksma, D. et al. Inadequate anti-oxidative responses in kidneys of brain-dead rats. *Transplantation* (2016). doi:10.1097/TP.0000000000001417
12. Kosieradzki, M. et al. Prognostic significance of free radicals: mediated injury occurring in the kidney donor. *Transplantation* **75**, 1221–1227 (2003).
13. Stiegler, P. et al. Oxidative stress and apoptosis in a pig model of brain death (BD) and living donation (LD). *J Transl Med* **11**, 244 (2013).
14. Jain, S. K. & Shohet, S. B. Calcium potentiates the peroxidation of erythrocyte membrane lipids. *Biochim. Biophys. Acta* **642**, 46–54 (1981).
15. Vladimirov, Y. A., Olenov, V. I., Suslova, T. B. & Cheremisina, Z. P. Lipid peroxidation in mitochondrial membrane. *Adv. Lipid Res.* **17**, 173–249 (1980).
16. Balibrea, J. M. et al. The differential tissue expression of inflammatory, oxidative stress, and apoptosis markers in human uncontrolled non-heart-beating donors. *Transplantation* **95**, 1346–1353 (2013).
17. Kosieradzki, M. & Rowiński, W. Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention. *Transplantation Proceedings* **40**, 3279–3288 (2008).
18. Nagelschmidt, M. et al. Lipid peroxidation products in machine perfusion of older donor kidneys. *J. Surg. Res.* **180**, 337–342 (2013).
19. Schnuelle, P. et al. Effects of donor pre-

- treatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. *JAMA* **302**, 1067–1075 (2009).
20. Niemann, C. U. & Malinoski, D. Therapeutic Hypothermia in Deceased Organ Donors and Kidney-Graft Function. *N. Engl. J. Med.* **373**, 2687 (2015).
 21. Guibert, E. E. *et al.* Organ Preservation: Current Concepts and New Strategies for the Next Decade. *Transfus Med Hemother* **38**, 125–142 (2011).
 22. Maathuis, M.-H. J., Leuvenink, H. G. D. & Ploeg, R. J. Perspectives in organ preservation. *Transplantation* **83**, 1289–1298 (2007).
 23. Moers, C., Pirenne, J., Paul, A., Ploeg, R. J. Machine Preservation Trial Study Group. Machine perfusion or cold storage in deceased-donor kidney transplantation. *N. Engl. J. Med.* **366**, 770–771 (2012).
 24. Zhao, D.-F., Dong, Q. & Zhang, T. Effects of Static Cold Storage and Hypothermic Machine Perfusion on Oxidative Stress Factors, Adhesion Molecules, and Zinc Finger Transcription Factor Proteins Before and After Liver Transplantation. *Ann. Transplant.* **22**, 96–100 (2017).
 25. Croce, A. C. *et al.* Fatty liver oxidative events monitored by autofluorescence optical diagnosis: Comparison between subnormothermic machine perfusion and conventional cold storage preservation. *Hepatol. Res.* **47**, 668–682 (2017).
 26. Henry, S. D. *et al.* Hypothermic machine preservation reduces molecular markers of ischemia/reperfusion injury in human liver transplantation. *Am J Transplant* **12**, 2477–2486 (2012).
 27. Downey, J. M. Free radicals and their involvement during long-term myocardial ischemia and reperfusion. *Annu. Rev. Physiol.* **52**, 487–504 (1990).
 28. Weyker, P. D., Webb, C. A. J., Kiamanesh, D. & Flynn, B. C. Lung ischemia reperfusion injury: a bench-to-bedside review. *Semin Cardiothorac Vasc Anesth* **17**, 28–43 (2013).
 29. Granger, D. N. & Kvietys, P. R. Reperfusion injury and reactive oxygen species: The evolution of a concept. *Redox Biology* **6**, 524–551 (2015).
 30. Snoeijs, M. G. J., van Heurn, L. W. E. & Buurman, W. A. Biological modulation of renal ischemia-reperfusion injury. *Curr Opin Organ Transplant* **15**, 190–199 (2010).
 31. Leindler, L. *et al.* Importance of cytokines, nitric oxide, and apoptosis in the pathological process of necrotizing pancreatitis in rats. *Pancreas* **29**, 157–161 (2004).
 32. Jarasch, E. D., Bruder, G. & Heid, H. W. Significance of xanthine oxidase in capillary endothelial cells. *Acta Physiol Scand Suppl* **548**, 39–46 (1986).
 33. Vickers, S., Schiller, H. J., Hildreth, J. E. & Bulkley, G. B. Immunoaffinity localization of the enzyme xanthine oxidase on the outside surface of the endothelial cell plasma membrane. *Surgery* **124**, 551–560 (1998).
 34. Land, W. G. Emerging role of innate immunity in organ transplantation part III: the quest for transplant tolerance via prevention of oxidative allograft injury and its consequences. *Transplant Rev (Orlando)* **26**, 88–102 (2012).
 35. Granger, D. N. & Kvietys, P. R. Redox Biology. *Redox Biology* **6**, 524–551 (2015).
 36. Hernandez, L. A. *et al.* Role of neutrophils in ischemia-reperfusion-induced microvascular injury. *Am. J. Physiol.* **253**, H699–703 (1987).
 37. Romson, J. L. *et al.* Reduction of the extent

- of ischemic myocardial injury by neutrophil depletion in the dog. *Circulation* **67**, 1016–1023 (1983).
38. Kuzuya, T. *et al.* Role of free radicals and neutrophils in canine myocardial reperfusion injury: myocardial salvage by a novel free radical scavenger, 2-octadecylascorbic acid. *Cardiovasc. Res.* **23**, 323–330 (1989).
 39. Jaeschke, H., Farhood, A. & Smith, C. W. Neutrophils contribute to ischemia/reperfusion injury in rat liver in vivo. *FASEB J.* **4**, 3355–3359 (1990).
 40. Smith, J. W. *et al.* Addition of direct peritoneal lavage to human cadaver organ donor resuscitation improves organ procurement. *J. Am. Coll. Surg.* **220**, 539–547 (2015).
 41. Victorino, G. P., Ramirez, R. M., Chong, T. J., Curran, B. & Sadjadi, J. Ischemia-reperfusion injury in rats affects hydraulic conductivity in two phases that are temporally and mechanistically separate. *Am. J. Physiol. Heart Circ. Physiol.* **295**, H2164–71 (2008).
 42. Sanderson, T. H., Reynolds, C. A., Kumar, R., Przyklenk, K. & Hüttemann, M. Molecular mechanisms of ischemia-reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxygen species generation. *Mol. Neurobiol.* **47**, 9–23 (2013).
 43. Zorov, D. B., Filburn, C. R., Klotz, L. O., Zweier, J. L. & Sollott, S. J. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. *J. Exp. Med.* **192**, 1001–1014 (2000).
 44. Kalogeris, T., Bao, Y. & Korthuis, R. J. Mitochondrial reactive oxygen species: a double edged sword in ischemia/reperfusion vs preconditioning. *Redox Biology* **2**, 702–714 (2014).
 45. Cardoso, S. *et al.* Perspectives on mitochondrial uncoupling proteins-mediated neuroprotection. *J. Bioenerg. Biomembr.* **47**, 119–131 (2015).
 46. Abu-Amara, M., Yang, S. Y., Seifalian, A., Davidson, B. & Fuller, B. The nitric oxide pathway—evidence and mechanisms for protection against liver ischaemia reperfusion injury. *Liver Int.* **32**, 531–543 (2012).
 47. Pernow, J. & Jung, C. Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal? *Cardiovasc. Res.* **98**, 334–343 (2013).
 48. Tratsiakovich, Y., Yang, J., Gonon, A. T., Sjöquist, P.-O. & Pernow, J. Arginase as a target for treatment of myocardial ischemia-reperfusion injury. *Eur. J. Pharmacol.* **720**, 121–123 (2013).
 49. Hale, A. N., Ledbetter, D. J., Gawriluk, T. R. & Rucker, E. B. Autophagy: regulation and role in development. *Autophagy* **9**, 951–972 (2013).
 50. Wei, Y., Pattingre, S., Sinha, S., Bassik, M. & Levine, B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. *Mol. Cell* **30**, 678–688 (2008).
 51. Liu, Y. & Levine, B. Autosis and autophagic cell death: the dark side of autophagy. *Cell Death and Differentiation* **22**, 367–376 (2015).
 52. Klionsky, D. J. & Emr, S. D. Autophagy as a regulated pathway of cellular degradation. *Science* **290**, 1717–1721 (2000).
 53. Slegtenhorst, B. R. *et al.* Mechanisms and Consequences of Injury and Repair in Older Organ Transplants. *Transplantation* **97**, 1091–1099 (2014).
 54. Kregel, K. C. & Zhang, H. J. An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **292**, R18–36

- (2007).
55. Pallet, N., Livingston, M. & Dong, Z. Emerging Functions of Autophagy in Kidney Transplantation. *Am J Transplant* **14**, 13–20 (2013).
 56. PhD, J.-P. D. *et al.* Autophagy and the Kidney: Implications for Ischemia-Reperfusion Injury and Therapy. *American Journal of Kidney Diseases* **66**, 699–709 (2015).
 57. Decuypere, J. P., Pirenne, J. & Jochmans, I. Autophagy in renal ischemia-reperfusion injury: friend or foe? *Am J Transplant* **14**, 1464–1465 (2014).
 58. Xu, Q. *et al.* Pharmacological modulation of autophagy to protect cardiomyocytes according to the time windows of ischaemia/reperfusion. *Br. J. Pharmacol.* **172**, 3072–3085 (2015).
 59. Yamaguchi, O. & Otsu, K. Role of autophagy in aging. *J. Cardiovasc. Pharmacol.* **60**, 242–247 (2012).
 60. Schiavi, A. & Ventura, N. The interplay between mitochondria and autophagy and its role in the aging process. *Exp. Gerontol.* **56**, 147–153 (2014).
 61. Terman, A. The effect of age on formation and elimination of autophagic vacuoles in mouse hepatocytes. *Gerontology* **41 Suppl 2**, 319–326 (1995).
 62. Chen, C. *et al.* Apoptosis and autophagy contribute to gender difference in cardiac ischemia-reperfusion induced injury in rats. *Life Sci.* **93**, 265–270 (2013).
 63. Kume, S. *et al.* Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. *J. Clin. Invest.* **120**, 1043–1055 (2010).
 64. Decuypere, J.-P. *et al.* Plasmatic villin 1 is a novel in vivo marker of proximal tubular cell injury during renal ischemia-reperfusion. *Transplantation* (2017). doi:10.1097/TP.0000000000001876
 65. Turkmen, K. *et al.* Apoptosis and autophagy in cold preservation ischemia. *Transplantation* **91**, 1192–1197 (2011).
 66. Cursio, R., Colosetti, P. & Gugenheim, J. Autophagy and liver ischemia-reperfusion injury. *Biomed Res Int* **2015**, 417590 (2015).
 67. Minor, T., Stegemann, J., Hirner, A. & Koetting, M. Impaired autophagic clearance after cold preservation of fatty livers correlates with tissue necrosis upon reperfusion and is reversed by hypothermic reconditioning. *Liver Transpl.* **15**, 798–805 (2009).
 68. Zaouali, M. A. *et al.* AMPK involvement in endoplasmic reticulum stress and autophagy modulation after fatty liver graft preservation: a role for melatonin and trimetazidine cocktail. *J. Pineal Res.* **55**, 65–78 (2013).
 69. Ma, S., Wang, Y., Chen, Y. & Cao, F. The role of the autophagy in myocardial ischemia/reperfusion injury. *Biochim. Biophys. Acta* **1852**, 271–276 (2015).
 70. Ma, X. *et al.* Impaired autophagosome clearance contributes to cardiomyocyte death in ischemia/reperfusion injury. *Circulation* **125**, 3170–3181 (2012).
 71. Kim, J.-S. *et al.* Carbamazepine suppresses calpain-mediated autophagy impairment after ischemia/reperfusion in mouse livers. *Toxicol. Appl. Pharmacol.* **273**, 600–610 (2013).
 72. Liu, S. *et al.* Autophagy plays a critical role in kidney tubule maintenance, aging and ischemia-reperfusion injury. *Autophagy* **8**, 826–837 (2012).
 73. Sciarretta, S., Hariharan, N., Monden, Y., Zablocki, D. & Sadoshima, J. Is autophagy in response to ischemia and reperfusion pro-

- protective or detrimental for the heart? *Pediatric Cardiol* **32**, 275–281 (2011).
74. Autophagy and the Kidney: Implications for Ischemia-Reperfusion Injury and Therapy. *American Journal of Kidney Diseases* **66**, 699–709 (2015).
 75. Scherz-Shouval, R. & Elazar, Z. ROS, mitochondria and the regulation of autophagy. *Trends Cell Biol.* **17**, 422–427 (2007).
 76. Filomeni, G., De Zio, D. & Cecconi, F. Oxidative stress and autophagy: the clash between damage and metabolic needs. *Cell Death and Differentiation* **22**, 377–388 (2015).
 77. Kiffin, R., Bandyopadhyay, U. & Cuervo, A. M. Oxidative stress and autophagy. *Antioxid. Redox Signal.* **8**, 152–162 (2006).
 78. Nacarelli, T., Torres, C. & Sell, C. in *link.springer.com* 169–185 (Springer International Publishing, 2016). doi:10.1007/978-3-319-26239-0_10
 79. Hoshino, A. *et al.* Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart. *Nat Commun* **4**, 2308 (2013).
 80. Youle, R. J. & Narendra, D. P. Mechanisms of mitophagy. *Nat. Rev. Mol. Cell Biol.* **12**, 9–14 (2011).
 81. Ichimura, Y. *et al.* Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. *Mol. Cell* **51**, 618–631 (2013).
 82. Cui, J. *et al.* Mitochondrial autophagy involving renal injury and aging is modulated by caloric intake in aged rat kidneys. *PLoS ONE* **8**, e69720 (2013).
 83. Akhtar, M. Z. *et al.* Using an Integrated -Omics Approach to Identify Key Cellular Processes That Are Disturbed in the Kidney After Brain Death. *Am J Transplant* **16**, 1421–1440 (2016).
 84. Rebolledo, R. A. *et al.* Anti-Apoptotic Effects of 3,3',5-Triiodo-L-Thyronine in the Liver of Brain-Dead Rats. *PLoS ONE* **10**, e0138749 (2015).
 85. Sinha, R. A. *et al.* Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy. *J. Clin. Invest.* **122**, 2428–2438 (2012).
 86. Sinha, R. A. *et al.* Thyroid hormone induction of mitochondrial activity is coupled to mitophagy via ROS-AMPK-ULK1 signaling. *Autophagy* **11**, 1341–1357 (2015).
 87. Southard, J. H. & Belzer, F. O. Organ preservation. *Annu. Rev. Med.* **46**, 235–247 (1995).
 88. Semmelmann, A. *et al.* Evaluation of preservation solutions by ESR-spectroscopy: superior effects of University of Wisconsin over Histidine-Tryptophan-Ketoglutarate in reducing renal reactive oxygen species. *Kidney International* **71**, 875–881 (2007).
 89. *Belzer UW® Cold Storage Solution (University of Wisconsin)*. (Bridge to Life). Available at: <http://www.bridgetolife.eu/wp-content/uploads/2012/12/english-cold-storage-belzer-uw-solution-usage-instructions-ifu.pdf>. (Accessed: 20 July 2017)
 90. Du, H. *et al.* Hydrogen-Rich Saline Attenuates Acute Kidney Injury After Liver Transplantation via Activating p53-Mediated Autophagy. *Transplantation* **100**, 563–570 (2016).
 91. Guixé-Muntet, S. *et al.* Cross-talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury. *J. Hepatol.* **66**, 86–94 (2017).
 92. Gracia-Sancho, J. *et al.* Simvastatin maintains function and viability of steatotic rat livers procured for transplantation. *J. Hepatol.* **58**, 1140–1146 (2013).
 93. Pantazi, E. *et al.* Sirtuin 1 in rat orthotopic

- liver transplantation: an IGL-1 preservation solution approach. *World J. Gastroenterol.* **21**, 1765–1774 (2015).
94. Schlegel, A., Kron, P. & Dutkowski, P. Hypothermic Oxygenated Liver Perfusion: Basic Mechanisms and Clinical Application. *Curr Transplant Rep* **2**, 52–62 (2015).
 95. Dutkowski, P., Schönfeld, S., Odermatt, B., Heinrich, T. & Junginger, T. Rat liver preservation by hypothermic oscillating liver perfusion compared to simple cold storage. *Cryobiology* **36**, 61–70 (1998).
 96. Lüer, B., Koetting, M., Efferz, P. & Minor, T. Role of oxygen during hypothermic machine perfusion preservation of the liver. *Transpl. Int.* **23**, 944–950 (2010).
 97. Shi, S. & Xue, F. Current Antioxidant Treatments in Organ Transplantation. *Oxid Med Cell Longev* **2016**, 8678510 (2016).
 98. Vairetti, M. *et al.* Subnormothermic machine perfusion protects steatotic livers against preservation injury: a potential for donor pool increase? *Liver Transpl.* **15**, 20–29 (2009).
 99. Lenaz, G. Mitochondria and reactive oxygen species. Which role in physiology and pathology? *Adv. Exp. Med. Biol.* **942**, 93–136 (2012).
 100. Petrosillo, G. *et al.* Mitochondrial dysfunction associated with cardiac ischemia/reperfusion can be attenuated by oxygen tension control. Role of oxygen-free radicals and cardiolipin. *Biochim. Biophys. Acta* **1710**, 78–86 (2005).
 101. Brown, D. A., Sabbah, H. N. & Shaikh, S. R. Mitochondrial inner membrane lipids and proteins as targets for decreasing cardiac ischemia/reperfusion injury. *Pharmacol. Ther.* **140**, 258–266 (2013).
 102. Chu, C. T. *et al.* Cardiolipin externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy in neuronal cells. *Nature Publishing Group* **15**, 1197–1205 (2013).
 103. Liu, Y. *et al.* Autosis is a Na⁺,K⁺-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia. *Proc. Natl. Acad. Sci. U.S.A.* **110**, 20364–20371 (2013).
 104. Li, J. *et al.* Astaxanthin Pretreatment Attenuates Hepatic Ischemia Reperfusion-Induced Apoptosis and Autophagy via the ROS/MAPK Pathway in Mice. *Mar Drugs* **13**, 3368–3387 (2015).
 105. Mitchell, T., Saba, H., Laakman, J., Parajuli, N. & MacMillan-Crow, L. A. Role of mitochondrial-derived oxidants in renal tubular cell cold-storage injury. *Free Radic. Biol. Med.* **49**, 1273–1282 (2010).
 106. Hariharan, N., Zhai, P. & Sadoshima, J. Oxidative stress stimulates autophagic flux during ischemia/reperfusion. *Antioxid. Redox Signal.* **14**, 2179–2190 (2011).
 107. van den Akker, E. K. *et al.* Ischemic postconditioning in human DCD kidney transplantation is feasible and appears safe. *Transplant International* **27**, 226–234 (2014).
 108. Soendergaard, P. *et al.* Improved GFR and renal plasma perfusion following remote ischaemic conditioning in a porcine kidney transplantation model. *Transpl. Int.* **25**, 1002–1012 (2012).
 109. Krogstrup, N. V. *et al.* Remote ischemic conditioning on recipients of deceased renal transplants does not improve early graft function: A multicentre randomised, controlled clinical trial. *Am J Transplant* (2016). doi:10.1111/ajt.14075
 110. Wei, C., Li, H., Han, L., Zhang, L. & Yang, X. Activation of autophagy in ischemic postconditioning contributes to cardioprotective effects against ischemia/reperfusion injury in rat hearts. *J. Cardiovasc. Pharmacol.* **61**, 416–422 (2013).

111. Wei, C. *et al.* Dopamine D2 receptors contribute to cardioprotection of ischemic post-conditioning via activating autophagy in isolated rat hearts. *Int. J. Cardiol.* **203**, 837–839 (2016).
112. Guo, L., Xu, J.-M. & Mo, X.-Y. Ischemic post-conditioning regulates cardiomyocyte autophagic activity following ischemia/reperfusion injury. *Mol Med Rep* **12**, 1169–1176 (2015).
113. Land, W. *et al.* The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. *Transplantation* **57**, 211–217 (1994).
114. Chen, Y., Azad, M. B. & Gibson, S. B. Superoxide is the major reactive oxygen species regulating autophagy. *Cell Death and Differentiation* **16**, 1040–1052 (2009).
115. van Gelder, T., van Schaik, R. H. & Hesselink, D. A. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation. *Nat Rev Nephrol* **10**, 725–731 (2014).
116. Lim, S. W. *et al.* Chronic cyclosporine nephropathy is characterized by excessive autophagosome formation and decreased autophagic clearance. *Transplantation* **94**, 218–225 (2012).
117. Settembre, C. *et al.* TFEB links autophagy to lysosomal biogenesis. *Science* **332**, 1429–1433 (2011).
118. Kim, D. *et al.* FK506, an Immunosuppressive Drug, Induces Autophagy by Binding to the V-ATPase Catalytic Subunit A in Neuronal Cells. *J. Proteome Res.* **16**, 55–64 (2017).
119. Długosz, A., Srednicka, D. & Boratyński, J. [The influence of tacrolimus on oxidative stress and free-radical processes]. *Postępy Hig Med Dosw (Online)* **61**, 466–471 (2007).
120. McTaggart, R. A. *et al.* Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. *Am J Transplant* **3**, 416–423 (2003).
121. Jolicoeur, E. M. *et al.* Combination therapy of mycophenolate mofetil and rapamycin in prevention of chronic renal allograft rejection in the rat. *Transplantation* **75**, 54–59 (2003).
122. Steiner, R. W. & Awdishu, L. Steroids in kidney transplant patients. *Semin Immunopathol* **33**, 157–167 (2011).
123. Torres, R. L. *et al.* Effects of acute and chronic administration of methylprednisolone on oxidative stress in rat lungs. *J Bras Pneumol* **40**, 238–243 (2014).

